Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 2Thoracic 1Sarcoma 1Gynecologic 1Genitourinary 1Dermatologic 1

Conditions

Sarcoma 85Osteosarcoma 37Melanoma 23Sarcoma, Ewing 22Rhabdomyosarcoma 19Ovarian Neoplasms 19Neuroblastoma 19Colorectal Neoplasms 18Gastrointestinal Stromal Tumors 17Glioblastoma 15Breast Neoplasms 15Bone Neoplasms 15Sarcoma, Kaposi 14Rhabdoid Tumor 14Neoplasms 14Wilms Tumor 13Liposarcoma 13Neoplasm Metastasis 12Gliosarcoma 12Glioma 12Carcinoma, Non-Small-Cell Lung 12Stomach Neoplasms 11Medulloblastoma 11Lymphoma, Non-Hodgkin 11Hepatoblastoma 11Neurofibrosarcoma 10Thyroid Neoplasms 9Recurrence 9Pancreatic Neoplasms 9Lymphoma 9

Interventions

enasidenib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Sinonasal undifferentiated carcinoma × Sarcoma × 30 days × Clear all
NCT06176989 2026-06-03

Enasidenib in IDH2-Mutated Malignant Sinonasal and Skull Base Tumors

National Institutes of Health Clinical Center (CC)

Phase 2 Recruiting
40 enrolled
CNSSarcoma

Sinonasal undifferentiated carcinoma, Chondrosarcoma, Esthesioneuroblastoma, Olfactory

Data powered by HemOnc (CC BY 4.0) Colophon âš¡